NASDAQ:AGRX

Agile Therapeutics Stock Forecast, Price & News

$1.08
+0.05 (+4.85 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.08
50-Day Range
$0.94
$1.37
52-Week Range
$0.93
$3.84
Volume698,951 shs
Average Volume619,083 shs
Market Capitalization$100.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95
30 days | 90 days | 365 days | Advanced Chart
Receive AGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Agile Therapeutics logo

About Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

386th out of 1,349 stocks

Pharmaceutical Preparations Industry

189th out of 663 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

Is Agile Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Agile Therapeutics stock.
View analyst ratings for Agile Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Agile Therapeutics?

Wall Street analysts have given Agile Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agile Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Agile Therapeutics
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its quarterly earnings results on Sunday, July, 25th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The specialty pharmaceutical company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.45 million.
View Agile Therapeutics' earnings history
.

How has Agile Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGRX stock has decreased by 44.3% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AGRX?

5 analysts have issued twelve-month target prices for Agile Therapeutics' stock. Their forecasts range from $1.03 to $6.00. On average, they anticipate Agile Therapeutics' stock price to reach $3.63 in the next year. This suggests a possible upside of 236.3% from the stock's current price.
View analysts' price targets for Agile Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the following people:
  • Al Altomari, Chairman & Chief Executive Officer
  • Dennis P. Reilly, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
  • Charles S. Grass, Senior Director-Finance
  • Paul Korner, Chief Medical Officer
  • Robert G. Conway, Chief Supply Chain Officer & Senior Vice President

Who are some of Agile Therapeutics' key competitors?

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.41%), Millennium Management LLC (1.62%), Royal Bank of Canada (1.07%), Renaissance Technologies LLC (0.90%), Morgan Stanley (0.83%) and Morgan Stanley (0.83%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for Agile Therapeutics
.

Which institutional investors are selling Agile Therapeutics stock?

AGRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, JPMorgan Chase & Co., and Principal Financial Group Inc..
View insider buying and selling activity for Agile Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Agile Therapeutics stock?

AGRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Morgan Stanley, Renaissance Technologies LLC, Tibra Equities Europe Ltd, GSA Capital Partners LLP, Ergoteles LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Agile Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $1.08.

How much money does Agile Therapeutics make?

Agile Therapeutics has a market capitalization of $100.44 million and generates $750,000.00 in revenue each year. The specialty pharmaceutical company earns $-51,850,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Agile Therapeutics have?

Agile Therapeutics employs 28 workers across the globe.

What is Agile Therapeutics' official website?

The official website for Agile Therapeutics is www.agiletherapeutics.com.

Where are Agile Therapeutics' headquarters?

Agile Therapeutics is headquartered at 101 POOR FARM ROAD, PRINCETON NJ, 08540.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.